WO2018106142A1 - Пептидный модулятор пуринергических рецепторов - Google Patents
Пептидный модулятор пуринергических рецепторов Download PDFInfo
- Publication number
- WO2018106142A1 WO2018106142A1 PCT/RU2017/000279 RU2017000279W WO2018106142A1 WO 2018106142 A1 WO2018106142 A1 WO 2018106142A1 RU 2017000279 W RU2017000279 W RU 2017000279W WO 2018106142 A1 WO2018106142 A1 WO 2018106142A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cys
- lys
- receptors
- pain
- gly
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 59
- 108010080192 Purinergic Receptors Proteins 0.000 title abstract description 11
- 102000000033 Purinergic Receptors Human genes 0.000 title abstract description 10
- 102100040460 P2X purinoceptor 3 Human genes 0.000 claims abstract description 53
- 101710189970 P2X purinoceptor 3 Proteins 0.000 claims abstract description 52
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 11
- 239000005557 antagonist Substances 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- 208000002193 Pain Diseases 0.000 abstract description 51
- 230000036407 pain Effects 0.000 abstract description 51
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 21
- 108090000623 proteins and genes Proteins 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 10
- 230000001404 mediated effect Effects 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 239000002773 nucleotide Substances 0.000 abstract description 5
- 125000003729 nucleotide group Chemical group 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 230000011664 signaling Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 239000000730 antalgic agent Substances 0.000 abstract description 3
- 230000001696 purinergic effect Effects 0.000 abstract description 3
- 229940035676 analgesics Drugs 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 21
- 102100040479 P2X purinoceptor 2 Human genes 0.000 description 19
- 101710189968 P2X purinoceptor 2 Proteins 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- 239000000556 agonist Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 230000007423 decrease Effects 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 102000002294 Purinergic P2X Receptors Human genes 0.000 description 7
- 108010000836 Purinergic P2X Receptors Proteins 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000000609 ganglia Anatomy 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 6
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 101710094933 Purotoxin-1 Proteins 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- KECTXGMVIXOQAO-UHFFFAOYSA-N purotoxin 1 Chemical compound N1C(=O)C(CCCNC(N)=N)NC(=O)C(C(C)CC)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CCC(O)=O)NC(=O)C(C)NC(=O)C(NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)CN)CSSCC(C(NC(C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)N2)C(C)O)=O)NC(=O)C(NC3=O)CSSCC(C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(CC(N)=O)NC(=O)C(CC=4C=CC(O)=CC=4)NC(=O)CNC(=O)C(CO)NC(=O)C(C)NC(=O)C(CC(N)=O)NC4=O)CSSCC4NC(=O)C(CCCCN)NC(=O)C2CSSCC1C(=O)NC(CC(O)=O)C(=O)NC(CC(O)=O)C(=O)NC(C(C)CC)C(=O)NC3CC1=CNC=N1 KECTXGMVIXOQAO-UHFFFAOYSA-N 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- CAWZRIXWFRFUQB-IOSLPCCCSA-N α,β Methylene ATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)CP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CAWZRIXWFRFUQB-IOSLPCCCSA-N 0.000 description 4
- 241000239290 Araneae Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000003637 basic solution Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000000586 desensitisation Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical class NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 210000000273 spinal nerve root Anatomy 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- VQGBOYBIENNKMI-LJAQVGFWSA-N 5-[(3-phenoxyphenyl)methyl-[(1s)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl]benzene-1,2,4-tricarboxylic acid Chemical compound C1=C(C(O)=O)C(C(=O)O)=CC(C(O)=O)=C1C(=O)N([C@@H]1C2=CC=CC=C2CCC1)CC1=CC=CC(OC=2C=CC=CC=2)=C1 VQGBOYBIENNKMI-LJAQVGFWSA-N 0.000 description 2
- 208000006561 Cluster Headache Diseases 0.000 description 2
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 229940126202 P2X3 receptor antagonist Drugs 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 206010065347 Premenstrual pain Diseases 0.000 description 2
- 101710094935 Purotoxin-2 Proteins 0.000 description 2
- 102400001227 Spinorphin Human genes 0.000 description 2
- 101800001235 Spinorphin Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940058936 antimalarials diaminopyrimidines Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000018912 cluster headache syndrome Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002708 spider venom Substances 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- VEKPWANJVWWTMM-DYDSHOKNSA-N spinorphin Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1[C]2C=CC=CC2=NC=1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C1=CC=C(O)C=C1 VEKPWANJVWWTMM-DYDSHOKNSA-N 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical class OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 208000009935 visceral pain Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 125000001894 2,4,6-trinitrophenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BJWWHDAQGDJZKY-UHFFFAOYSA-N 3-phenyl-1H-thieno[3,2-c]pyrazole Chemical compound C1(=CC=CC=C1)C1=NNC2=C1SC=C2 BJWWHDAQGDJZKY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101000844262 Alopecosa marikovskyi Purotoxin-1 Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001012451 Homo sapiens Enteropeptidase Proteins 0.000 description 1
- 101000614332 Homo sapiens P2X purinoceptor 3 Proteins 0.000 description 1
- HAEJPQIATWHALX-KQYNXXCUSA-N ITP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-N 0.000 description 1
- 102100037644 Kelch-like protein 41 Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100040444 P2X purinoceptor 1 Human genes 0.000 description 1
- 101710189973 P2X purinoceptor 1 Proteins 0.000 description 1
- 102100037601 P2X purinoceptor 4 Human genes 0.000 description 1
- 101710189967 P2X purinoceptor 4 Proteins 0.000 description 1
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 1
- 101710189965 P2X purinoceptor 7 Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 241000094374 Thomisus onustus Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QTPILKSJIOLICA-UHFFFAOYSA-N bis[hydroxy(phosphonooxy)phosphoryl] hydrogen phosphate Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(O)=O QTPILKSJIOLICA-UHFFFAOYSA-N 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates to medicine and pharmacology, in particular to biologically active peptides that modify purinergic signaling and can be used for the prevention and treatment of diseases whose pharmacological target are purinergic receptors.
- NSAIDs non-steroidal anti-inflammatory drugs
- corticosteroid steroidal (corticosteroid) drugs
- antidepressants and anticonvulsants
- strong or weak opiates NSAIDs form the most prescribed class of therapeutic drugs in the world due to their high effectiveness, both in relation to the inflammatory process and in relation to pain itself. They are used for all types of inflammatory pain, both acute and chronic.
- NSAIDs are very effective, nevertheless, they remain a serious source of unwanted side effects, which limits the use of NSAIDs in numerous clinical situations.
- many types of pain remain slightly sensitive to known analgesics, therefore, the development of new analgesic agents with a new mechanism of action is an important and urgent task.
- Ionotropic purinergic receptors are ligand-controlled ion channels, the natural agonist of which is adenosine triphosphate (ATP), applied from the extracellular side. These receptors are found in various organs and tissues, of particular physiological importance is their function in the nervous system [Surprenant A., North RA Signaling at purinergic P2X receptors // Annu. Rev. Physiol., 2009, Vol. 71, p. 333-359]. They are expressed in sensitive neurons, and ATP released from damaged or inflamed tissues activates P2X receptors and initiates pain signals. Purinergic signaling is believed to play an important role in pain conditions associated with injuries, tumors, inflammation, migraines, and respiratory diseases.
- ATP adenosine triphosphate
- Selective modulators of the function of purinergic receptors which are able to modulate the work of only certain isoforms, are the basis for the creation of drugs for the treatment of diseases in the development of which these receptors participate, and are also necessary for studying the functions of purinergic receptors.
- receptor antagonists inhibitors
- P2X3 receptors receptor antagonists (inhibitors) have the greatest pharmacological potential, since it is precisely the decrease in their activity that is required for the treatment of a number of pain syndromes.
- P2X3 receptors many low molecular weight antagonists of P2X3 receptors are known, for example: 2 ', 3'-0- (2,4,6-trinitrophenyl) -ATP [Virginio C. et al. Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2 / 3 receptors // Mol. Pharmacol., 1998, Vol. 53, p. 969-973], other derivatives of mono- and dinucleotides [Ford K.K. et al.
- P2X3 antagonist P1, P5-di [inosine-5 '] pentaphosphate binds to the desensitized state of the receptor in rat dorsal root ganglion neurons // J. Pharmacol. Exp. Ther., 2005, Vol. 315, p. 405-413; US 6.881, 725], analogues of suramin [Hausmann R. et al.
- the suramin analog 4,4 ', 4 ", 4'” - (carbonylbis (imino-5,1 > 3-benzenetriylbis (carbonylimimino))) tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups // Mol. Pharmacol., 2006, Vol. 69, p. 2058-2067], antagonist A-317491 [Jarvis MF et al. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2 / 3 receptors, reduces chronic inflammatory and neuropathic pain in the rat // Proc.
- P2X3 receptors are also known substances of a protein nature: spinorphin, a fragment of the hemoglobin ⁇ -chain, which also affects other targets [Jung KY et al. Structure-activity relationship studies of spinorphin as a potent and selective human P2X3 receptor antagonist // J. Med. Chem., 2007, Vol. 50, p. 4543-4547], and two components of the poison of the spider Alopecosa marikovskyi - purotoxin-1 (PT1) [Grishin EV et al. Novel peptide from spider venom inhibits P2X3 receptors and inflammatory pain // Ann. Neurol., 2010, Vol. 67, p.
- PT1 spider Alopecosa marikovskyi - purotoxin-1
- PT1 is the closest analogue of the claimed compounds. This peptide consists of 35 amino acid residues and selectively inhibits the activity of P2X3 receptors by stabilizing their desensitized state. Recombinant PT1 can be obtained in the bacterial expression system [Grishin EV et al. Novel peptide from spider venom inhibits P2X3 receptors and inflammatory pain // Ann. Neurol., 2010, Vol. 67, p. 680-683; RU2422459; RU257194].
- the objective of the invention is to develop and obtain new effective antagonists of purinergic P2X3 receptors, promising for use in clinical practice.
- the technical result of the invention is to obtain new effective peptides that modulate the activity of P2X3 purinergic receptors, as well as having selectivity for P2X3, high stability and are promising for use in the treatment of diseases or conditions of a mammal, the pharmacological target of which are P2X3 purinergic receptors, in particular pain of various etiologies.
- an additional technical result is that the peptides according to the invention are simple in structure compared to the prototype, and can be easily obtained in the bacterial expression system, therefore, the peptides according to the invention are promising for creating drugs based on them.
- the specified technical result is achieved through the development and preparation of a peptide that modulates the activity of P2X3 purinergic receptors having the following amino acid sequence:
- the peptide modulating the activity of P2X3 purinergic receptors has the following amino acid sequence:
- the peptide modulating the activity of P2X3 purinergic receptors has the following amino acid sequence:
- the present invention also relates to the use of the subject peptides as modulators of P2X3 purinergic receptors.
- the present invention also relates to the use of the subject peptides as antagonists of P2X3 purinergic receptors.
- the present invention also relates to the use of the subject peptides for the preparation of a pharmaceutical composition for the treatment and / or prevention of conditions associated with P2X3 purinergic receptors, for example, in the treatment of pain of various etiologies and / or symptoms of pain, in particular pain after inflammation, postoperative pain, visceral pain, toothache, premenstrual pain, pain caused by burns, migraine or cluster headache, pain with nerve damage, neuritis, neuralgia, pain with cancer diseases or pain associated with irritable bowel syndrome.
- the invention also includes the preparation of the peptides of the invention. These peptides can be obtained by genetic engineering or chemical synthesis.
- PT6 peptide refers to a peptide having the following amino acid sequence:
- modulate means changing the functional characteristics of P2X purinergic receptors (in particular, inhibiting, blocking, decreasing or preventing physiological effects caused by the binding of an agonist (including an endogenous agonist) to the receptor), in particular, P2X3 receptors.
- modulator means a substance capable of modulating, that is, altering the functional characteristics of P2X purinergic receptors (in particular, inhibiting, blocking, decreasing or preventing physiological effects caused by binding of an agonist (including an endogenous agonist) to the receptor), in particular P2X3 receptors.
- antagonist in biochemistry and pharmacology is meant a subtype of ligands for cell receptors.
- a ligand with receptor antagonist properties is a ligand that inhibits, blocks, reduces or prevents the physiological effects caused by the binding of an agonist (including an endogenous agonist) to the receptor.
- a “selective” antagonist is called if it inhibits a specific receptor or receptor subtype. The degree of selectivity may vary.
- homologous in the present invention is synonymous with the term “identity” and means the similarity of sequences of peptide molecules.
- identity means the similarity of sequences of peptide molecules.
- the degree of sequence identity means a comparison between amino acid sequences and is determined by comparing two optimally aligned sequences in the comparison window, while part of the amino acid sequence in the comparison window may contain inserts or deletions (i.e. spaces) compared to the control sequence (not containing insertions or deletions) to optimally align the two sequences.
- the degree of identity can be calculated by determining the number of positions at which identical amino acid residues are found in both sequences, obtaining the number of matching positions, dividing the number of matching positions by the total number of positions in the comparison window, and multiplying the result by 100, obtaining the degree of sequence identity in percent.
- Professionals should be aware that there are many established algorithms for aligning two sequences. Examples of algorithms suitable for determining the degree of sequence identity are BLAST and BLAST 2.0 [Altschul SF et al. Basic local alignment search tool // J. Mol. Biol., 1990, Vol. 215, p. 403-410; Altschul SF et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs // Nucleic Acids Res., 1997, Vol. 25, p. 3389-3402].
- homologous peptides have identical or similar amino acid sequences.
- similar residues are “conservative substitutions” or “allowed point mutations” of the corresponding amino acid residues in the control sequence.
- Conservative substitutions of residues in the control sequence are those that are physically or functionally similar to the corresponding control residue, for example, have a similar size, shape, electric charge, chemical properties, including the ability to form covalent or hydrogen bonds, and the like.
- all homologous peptide sequences that are the subject of the invention have the ability to effectively modulate the activity of P2X3 receptors.
- treatment means a method of obtaining favorable or desired clinical results.
- favorable or desired clinical results include, but are not limited to, one or more of the following aspects: reducing any manifestation, in particular, pain of various etiologies, including the intensity of the pain, relieving one or more symptoms of pain, including any symptom pain, such as reducing the duration of pain and / or reducing the perception or sensation of pain, temporarily relieving and / or slowing the development of pain.
- reducing the manifestation” of pain means any means of alleviating pain (which may include reducing the need for drugs and / or reducing the number of other drugs commonly used in these conditions), reducing the duration, intensity and / or frequency of pain (including, for example , an increase in the time until the subject has pain of various etiologies).
- the term “decrease in intensity” of pain of various etiologies means the weakening or improvement of one or more symptoms of pain compared with pain that occurs without the introduction of a modulator of P2X3 receptors.
- the term “decrease in intensity” also means a decrease in the duration of the symptom.
- the term "temporary relief" of pain of various etiologies or of one or more symptoms of pain means a decrease in the degree of manifestation of one or several undesirable clinical signs of pain in one or more subjects treated with a P2X3 receptor modulator in accordance with the present invention.
- the term "slowing down" the development of pain of various etiologies means inhibiting, inhibiting, delaying, stabilizing and / or delaying the progression of pain. Such a slowdown may vary in time depending on the medical history and / or subject to be treated. As should be obvious to a person skilled in the art, a significant or significant slowdown may in fact include the prevention of pain, expressed in that the subject does not experience pain.
- the method of "slowing down" the development of a symptom is a method that reduces the likelihood of a symptom occurring in a given period of time and / or reduces the degree of symptom manifestation in a given period of time compared to a situation where this method is not applied. Such comparisons are usually based on clinical trials involving a sufficient number of subjects to obtain a statistically significant result.
- FIGURE 2 Effect of the PT6 peptide on currents mediated by P2X receptors in a culture of neurons from the ganglia of the dorsal roots of the rat spinal cord.
- the histogram shows the relative value of the residual currents (I) mediated by homogeneous P2X3, heteromeric P2X2 / 3 and homomeric P2X2 receptors when RTb is applied at a concentration of 50 nM compared to control currents in the absence of PT6 (l 0 ).
- the problem of this invention is solved by obtaining peptides according to the invention, modulating the activity of P2X3 purinergic receptors.
- the sequence of the PT6 peptide is determined by analysis of mRNA from the poisonous glands of araneomorphic spiders, namely, the indicated sequence of the PT6 peptide is determined by analysis of the codNA library of the glands of the spider Thomisus onustus.
- the peptides of the invention, and in particular the PT6 peptide are substances of a polypeptide (protein) nature and can be obtained by chemical synthesis or by genetic engineering. It was unexpectedly discovered that the claimed peptides are able to inhibit P2X3 purinergic receptors. So, in particular, the PT6 peptide at a concentration of 50 nM causes 80% inhibition of currents mediated by P2X3 receptors in rat sensory neurons. PT6 is a selective antagonist of P2X3 purinergic receptors.
- the peptide-based preparations of the invention are promising for use in the treatment of pains of various etiologies, in particular, pain with inflammation, postoperative pain, visceral pain, toothache, premenstrual pain, pain caused by burns, migraine or cluster headache, pain with nerve damage , neuritis, neuralgia, pain with cancer or pain associated with irritable bowel syndrome.
- the peptides of the invention can be used, in particular, to reduce the manifestation of pain, to reduce the intensity of pain, to temporarily relieve pain or to slow the development of pain of various etiologies.
- the peptide PT6 is characterized by an extremely stable structure.
- the amino acid sequence of the PT6 peptide is converted to its corresponding nucleotide sequence, taking into account the frequency of codon use in Escherichia coli.
- Several oligonucleotide fragments up to 50 nucleotides in length are synthesized, overlapping the entire sequence of the PT6 gene, while the terminal ones contain restriction sites for cloning into the pET-32b plasmid (Novagen, USA): f1, 5'-TTTCGGTACCGGCTATTGCGCGACCAAAGGCATTAAATGCAA-3 ',
- PCR polymerase chain reaction
- phosphorylation of the 3'-ends of the fragments is carried out using polynucleotide kinase (Promega, USA) at 37 ° C for 30 minutes
- ligation is carried out using phage T4 DNA ligase (Promega, USA) for 18 hours at 16 ° C.
- PCR is carried out according to the standard procedure on a PCR-amplifier RTS-200 (MJ Research, USA).
- the reaction mixture contains a PCR buffer solution (50 mM KCI, 1, 5 mM MgCI 2 , 0.1% Tween 20, 50 mM Tris-HCI, pH 8.6), a mixture of four deoxynucleotides (Promega, USA), primer (terminal ) oligonucleotides (5'-GGCTATTGCGCGACCA-3 'and S'-TTAGCCTTTCACGCACAC-S'), template DNA (ligase mixture) and Taq polymerase.
- PCR conditions denaturation (96 ° C) - 20 sec .; annealing (50 ° ⁇ ) - 20 sec .; elongation (72 ° C) - 30 sec., 25 cycles.
- the obtained plasmids are used to transform E. coli cells of strain XL1 Blue using the Cellject electroporator (Eurogentec, Belgium).
- the parameters of the electric pulse are set according to the recommendations of the manufacturer of the electroporator.
- the cell suspension is transferred to a Petri dish with solid LB medium (1% bactotryptone, 0.5% yeast extract, 1% NaCI, 1, 5% agar, 10 mM Tris-HCI, pH 7.6) with the addition of ampicillin (70 ⁇ g / ml) as a selective factor. Plates are incubated at 37 ° C for 18 hours.
- coli XL1 Blue colonies obtained on selective medium after transformation are scattered by streaks on a new Petri dish with solid LB medium and ampicillin (70 ⁇ g / ml).
- the plates are incubated for 18 hours at 37 ° C.
- PCR is performed with sequence-specific oligonucleotide primers (5'-GGCTATTGCGCGACCA-3 'and 5'- TTAGCCTTTCACGCACAC-3 '), total nucleic acid from the obtained cell mass is used as a matrix.
- Selected transformants are used to obtain an overnight liquid culture in 5 ml of LB liquid medium with the addition of ampicillin (70 ⁇ g / ml), the suspension is incubated for 18 h at 37 ° C.
- the preparative isolation of plasmid DNA is carried out using the Wizard Plus SV Minipreps DNA Purification System reagent kit (Promega, USA) in accordance with the manufacturer's procedure.
- the production of the chimeric protein is carried out using the controlled expression of the corresponding gene in E. coli cells of strain BL21 (DE3).
- Cells are pelleted by centrifugation (10 min, 4500 rpm) and resuspended in 25 ml of start affinity chromatography buffer (see below) with the addition of 1% Triton X-100.
- the destruction of cell structures is carried out using an ultrasonic disintegrator CPX 750 (Cole-Parmer Instruments, USA).
- Isolation of the fusion protein is carried out using affinity chromatography.
- the cell lysate is applied in the start buffer (50 mM Tris-HCI, pH 8, 300 mM NaCI) onto a 3 ml column with TALON Superflow Metal Affinity Resin resin (Clontech, USA) at a flow rate of 1 ml / min.
- a buffer containing 50 mM Tris-HCI, pH 8, 300 mM NaCI, 150 mM imidazole is used. Detection is carried out by optical absorption of the eluate at 280 nm. The isolation and purification of the hybrid protein is controlled by electrophoresis of aliquots of the obtained fractions in a polyacrylamide gel.
- the resulting protein is subjected to desalination on a Jupiter C 4 column (10 * 250 mm, 300 A, 10 ⁇ m; Phenomenex, USA). Elution is carried out by a stepwise change in the concentration of acetonitrile (0-70%) in 0.1% trifluoroacetic acid (TFA) with a flow rate of 2 ml / min.
- TFA trifluoroacetic acid
- the protein is dried in a vacuum concentrator, dissolved in 50 mm Tris-HCI, pH 8, the final protein concentration is ⁇ 1 mg / ml.
- To solution protein add a solution of the catalytic subunit of human enteropeptidase at the rate of 1 unit per 1 mg of protein, hydrolysis is carried out at room temperature for 18 hours.
- the individuality of the obtained PT6 preparation is confirmed by repeated chromatography on a Vydac 218TP54 C 18 column column (4.6x250 mm, 300 A, 5 ⁇ m; Separations Group, USA) in a linear gradient of acetonitrile concentration (0-30% for 30 min) in 0.1% TFA at a flow rate of 1 ml / min ( Figure 1 B).
- the result is a recombinant PT6 yield of 5 mg with 1 L of bacterial culture.
- the structure of the recombinant peptide is confirmed by mass spectrometry and ⁇ -terminal sequencing.
- mice The peptides of the invention were tested for their ability to modulate P2X receptor activity.
- Experimental neurons are isolated from the ganglia of the dorsal roots of the spinal cord (posterior radicular ganglia) of 9-12-day-old Wistar rats.
- the ganglia are placed in a Petri dish filled with an extracellular solution (130 mM NaCI, 5 mM KCI, 2 mM CaCI 2 , 2 mM gCI 2 , 20 mM HEPES, pH 7.4) at room temperature, and then in an enzyme solution (1 mg trypsin and 2 mg of collagenase in 2 ml of extracellular solution), heated to 35 ° C, incubated for 10 minutes Then the ganglia are thoroughly washed with a clean (without enzymes) extracellular solution in another Petri dish. Single cells are isolated from the washed ganglia using thin needles. A single-cell cup is transferred to an electrophysiological setup. The experiments begin after all the cells have settled to the bottom of the plate after 30 minutes. after isolation.
- an extracellular solution 130 mM NaCI, 5 mM KCI, 2 mM CaCI 2 , 2 mM gCI 2 , 20 mM HEPES, pH 7.4
- an enzyme solution (1 mg tryp
- Electrophysiological testing is carried out using the classical method of local potential clamping (patch clamp) in the configuration of voltage removal from the whole cell (whole cell) using the approach of rapid application of a substance (agonist), which binds to P2X3 receptors and causes the opening of the ion channel.
- the electrophysiological installation consists of three parts: a microscope, a system for applying substances to the cell (“jumping table”; Pharma Robot, Ukraine) and registration systems for currents flowing through channels in the plasma membrane of a cell. Isolated neurons in a Petri dish are placed under a microscope with phase contrast on the setup. For the experiment, cells with a diameter of 8-12 ⁇ m are selected.
- a glass pipette electrode filled with an intracellular solution (120 mM CsF, 10 mM Tris-HCI, pH 7.2) is brought to the selected cell, as a result, a tight contact is formed between the pipette and the cell membrane with a resistance of the order of G ⁇ . Then the cell on the pipette is lifted from the bottom of the cup and placed in the application tube.
- the solutions used in the experiment are in the chambers of the bouncing table.
- solution 1 the basic extracellular solution in which the obtained cells are stored
- solution 2 the basic solution with the addition of an agonist in the required concentration
- solution 3 the basic solution with the PT6 peptide in the required concentration
- solution 4 the basic solution with agonist and peptide PT6 in the required concentrations.
- the washing procedure is carried out at least 15 times over 3 minutes. After 3 minutes after application of the agonist, the procedure is repeated. After obtaining control currents, a PT6 peptide is applied to the cell. Next, repeat the procedure for applying the agonist with PT6. After application of the agonist together with PT6, washing of the cells from the agonist is also carried out against the background of PT6.
- the sequential application of an agonist with PT6 is stopped when the amplitude of the P2X-mediated current remains unchanged.
- the ratio of the amplitude of the control current to the steady-state amplitude of the current against the background of a certain concentration of PT6 is an indicator of the effectiveness of the given concentration of PT6.
- Currents are recorded at a supported potential of -60 mV and room temperature using a model 2400 amplifier (AM Systems, USA). Electrodes for electrophysiological studies are made of borosilicate glass on a P-97 Flamming / Brown installation (Sutter Instrument, USA); their resistance is 3-5 M ⁇ .
- As an agonist cytidine triphosphate (CTF) is used in a saturating concentration (100 ⁇ M).
- a current with a fast rise phase (up to 12 ms) and a fast decline phase (up to 500 ms) corresponds to a current mediated by P2X3 receptors.
- the activation time of the receptors is 2-4 ms
- the desensitization time is 20-100 ms
- the release time of the receptors from desensitization is about 2 minutes for CTF.
- the binding of the PT6 peptide to P2X3 receptors in a desensitized state leads to a significant decrease in the current amplitude.
- PT6 leads to a decrease in the amplitude of the current mediated by P2X3 receptors by 80% ( Figure 2).
- the PT6 peptide is a modulator, namely an antagonist, of P2X3 purinergic receptors.
- the exit time from desensitization of P2X3 receptors is very long compared with P2X2 and P2X2 / 3 receptors.
- P2X2 and P2X2 / 3 receptors When applying an agonist with a period of 1 min, all the observed responses, except the first, are mediated by P2X2 and P2X2 / 3 receptors.
- the sensitivity of the P2X2 / 3 receptor to ATP and to ⁇ , ⁇ -methylene-ATP is approximately the same (Kd ⁇ 30 ⁇ M), and the minimum concentration of ⁇ , ⁇ -methylene-ATP required for activation of P2X2 receptors is at least 100 ⁇ M.
- the equivalence of ion currents observed in response to the alternate application of ATP and ⁇ , ⁇ -methylene-ATP indicates a significant predominance of P2X2 / 3 receptors in the cell membrane.
- the membrane contains mainly P2X2 receptors.
- PT6 does not affect the ionic currents mediated by P2X2 / 3 and P2X2 receptors ( Figure 2).
- the PT6 peptide acts selectively on P2X3 isoform receptors and is a selective antagonist of P2X3 purinergic receptors.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/466,885 US10981958B2 (en) | 2016-12-06 | 2017-05-31 | Peptide modulator of purinergic receptors |
JP2019531251A JP6870091B2 (ja) | 2016-12-06 | 2017-05-31 | プリン受容体のペプチドモジュレータ |
KR1020197019434A KR102237590B1 (ko) | 2016-12-06 | 2017-05-31 | 퓨린성 수용체의 펩티드 조절자 |
EA201991365A EA037272B1 (ru) | 2016-12-06 | 2017-05-31 | Пептидный модулятор пуринергических рецепторов |
CA3045790A CA3045790C (en) | 2016-12-06 | 2017-05-31 | Peptide modulator of purinergic receptors |
EP17877931.0A EP3584254A4 (en) | 2016-12-06 | 2017-05-31 | PEPTIDE MODULATOR OF PURINERGIC RECEPTORS |
AU2017371488A AU2017371488B2 (en) | 2016-12-06 | 2017-05-31 | Peptide modulator of purinoceptors |
CN201780076067.5A CN110062763B (zh) | 2016-12-06 | 2017-05-31 | 嘌呤能受体的肽调节剂 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2016147736 | 2016-12-06 | ||
RU2016147736A RU2650780C1 (ru) | 2016-12-06 | 2016-12-06 | Пептидный модулятор пуринергических рецепторов |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018106142A1 true WO2018106142A1 (ru) | 2018-06-14 |
Family
ID=61976543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2017/000279 WO2018106142A1 (ru) | 2016-12-06 | 2017-05-31 | Пептидный модулятор пуринергических рецепторов |
Country Status (10)
Country | Link |
---|---|
US (1) | US10981958B2 (ru) |
EP (1) | EP3584254A4 (ru) |
JP (1) | JP6870091B2 (ru) |
KR (1) | KR102237590B1 (ru) |
CN (1) | CN110062763B (ru) |
AU (1) | AU2017371488B2 (ru) |
CA (1) | CA3045790C (ru) |
EA (1) | EA037272B1 (ru) |
RU (1) | RU2650780C1 (ru) |
WO (1) | WO2018106142A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2714114C1 (ru) * | 2019-08-30 | 2020-02-11 | Общество с ограниченной ответственностью «Анальгетики будущего» | Способ получения пептида, модулирующего активность пуринергических рецепторов |
CN113151128B (zh) * | 2021-03-11 | 2022-04-05 | 厦门宝太生物科技股份有限公司 | 一种用于新型冠状病毒n蛋白表达的大肠杆菌表达培养基 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6881725B2 (en) | 2002-02-01 | 2005-04-19 | Inspire Pharmaceuticals Inc. | Method for treating pain |
US7491821B2 (en) | 2005-08-15 | 2009-02-17 | Roche Palo Alto Llc | Inhibitors of P2X3 |
US7531547B2 (en) | 2005-09-01 | 2009-05-12 | Roche Palo Alto Llc | Diaminopyrimidines as P2X3 and P2X2/3 modulators |
US7589090B2 (en) | 2007-02-28 | 2009-09-15 | Roche Palo Alto Llc | Diaminopyrimidines as P2X3 and P2X2/3 modulators |
US7595405B2 (en) | 2006-06-29 | 2009-09-29 | Roche Palo Alto Llc | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
RU2422459C1 (ru) | 2010-06-01 | 2011-06-27 | Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН | Пептидный модулятор пуринергических рецепторов |
RU2571942C2 (ru) * | 2013-11-14 | 2015-12-27 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ получения рекомбинантного анальгетического пептида |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2624379A1 (en) * | 2005-09-30 | 2007-04-12 | Merck & Co., Inc. | Nucleic acids encoding a functional mammalian purinoreceptor, p2x3, methods of production and use thereof |
KR101698153B1 (ko) * | 2010-04-26 | 2017-01-23 | 광주과학기술원 | P2x1 및 p2x3 수용체 길항제로 사용되는 신규한 피리딘 카르복실산계 화합물, 이의 제조방법 및 이를 포함하는 조성물 |
-
2016
- 2016-12-06 RU RU2016147736A patent/RU2650780C1/ru active
-
2017
- 2017-05-31 US US16/466,885 patent/US10981958B2/en active Active
- 2017-05-31 CN CN201780076067.5A patent/CN110062763B/zh active Active
- 2017-05-31 EA EA201991365A patent/EA037272B1/ru unknown
- 2017-05-31 AU AU2017371488A patent/AU2017371488B2/en active Active
- 2017-05-31 WO PCT/RU2017/000279 patent/WO2018106142A1/ru unknown
- 2017-05-31 EP EP17877931.0A patent/EP3584254A4/en active Pending
- 2017-05-31 CA CA3045790A patent/CA3045790C/en active Active
- 2017-05-31 KR KR1020197019434A patent/KR102237590B1/ko active IP Right Grant
- 2017-05-31 JP JP2019531251A patent/JP6870091B2/ja active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6881725B2 (en) | 2002-02-01 | 2005-04-19 | Inspire Pharmaceuticals Inc. | Method for treating pain |
US7491821B2 (en) | 2005-08-15 | 2009-02-17 | Roche Palo Alto Llc | Inhibitors of P2X3 |
US7531547B2 (en) | 2005-09-01 | 2009-05-12 | Roche Palo Alto Llc | Diaminopyrimidines as P2X3 and P2X2/3 modulators |
US7595405B2 (en) | 2006-06-29 | 2009-09-29 | Roche Palo Alto Llc | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
US7589090B2 (en) | 2007-02-28 | 2009-09-15 | Roche Palo Alto Llc | Diaminopyrimidines as P2X3 and P2X2/3 modulators |
RU2422459C1 (ru) | 2010-06-01 | 2011-06-27 | Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН | Пептидный модулятор пуринергических рецепторов |
RU2571942C2 (ru) * | 2013-11-14 | 2015-12-27 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ получения рекомбинантного анальгетического пептида |
Non-Patent Citations (18)
Title |
---|
ALTSCHUL S.F. ET AL.: "Basic local alignment search tool", J. MOL. BIOL., vol. 215, 1990, pages 403 - 410, XP002949123, DOI: doi:10.1006/jmbi.1990.9999 |
ALTSCHUL S.F. ET AL.: "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402, XP002905950, DOI: doi:10.1093/nar/25.17.3389 |
BROTHERTON-PLEISS C.E.: "Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist", BIOORG. MED. CHEM. LETT., vol. 20, 2010, pages 1031 - 1036, XP026861861 |
BURGARD E.C. ET AL.: "P2X receptor-mediated ionic currents in dorsal root ganglion neurons", J. NEUROPHYSIOL., vol. 82, 1999, pages 1590 - 1598 |
CARTER D.S. ET AL.: "Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X3/P2X2/3 antagonist for the treatment of pain", BIOORG. MED. CHEM. LETT., vol. 19, 2009, pages 1628 - 1631, XP026005841, DOI: doi:10.1016/j.bmcl.2009.02.003 |
DONNELLY-ROBERTS D. ET AL.: "Painful purinergic receptors", J. PHARMACOL. EXP. THER., vol. 324, 2008, pages 409 - 415 |
FORD K.K. ET AL.: "The P2X3 antagonist P1, P5-di[inosine-5'] pentaphosphate binds to the desensitized state of the receptor in rat dorsal root ganglion neurons", J. PHARMACOL. EXP. THER., vol. 315, 2005, pages 405 - 413 |
GRISHIN E.V. ET AL.: "Novel peptide from spider venom inhibits P2X3 receptors and inflammatory pain", ANN. NEUROL., vol. 67, 2010, pages 680 - 683, XP055510237, DOI: doi:10.1002/ana.21949 |
GRISHIN E.V. ET AL.: "Novel Peptide from Spider Venom Inhibits P2X3 Receptors and Inflammatory Pain", ANNALS OF NEUROLOGY, vol. 67, no. 5, 2010, pages 680 - 683, XP055510237 * |
HAUSMANN R. ET AL.: "The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups", MOL. PHARMACOL., vol. 69, 2006, pages 2058 - 2067 |
JAHANGIR A. ET AL.: "Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X3/P2X2/3 antagonist for the treatment of pain", BIOORG. MED. CHEM. LETT., vol. 19, 2009, pages 1632 - 1635, XP026005842, DOI: doi:10.1016/j.bmcl.2009.01.097 |
JARVIS M.F. ET AL.: "A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat", PROC. NATL. ACAD. SCI. U. S. A., vol. 99, 2002, pages 17179 - 17184, XP008113908, DOI: doi:10.1073/pnas.252537299 |
JUNG K.Y. ET AL.: "Structure-activity relationship studies of spinorphin as a potent and selective human P2X3 receptor antagonist", J. MED. CHEM., vol. 50, 2007, pages 4543 - 4547 |
KABANOVA N.V. ET AL.: "Modulation of P2X3 receptors by spider toxins", BIOCHIM. BIOPHYS. ACTA, vol. 1818, 2012, pages 2868 - 2875 |
See also references of EP3584254A4 |
SURPRENANT A.NORTH R.A.: "Signaling at purinergic P2X receptors", ANNU. REV. PHYSIOL., vol. 71, 2009, pages 333 - 359 |
VIRGINIO C. ET AL.: "Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors", MOL. PHARMACOL., vol. 53, 1998, pages 969 - 973, XP002919965 |
WIRKNER K. ET AL.: "P2X3 receptor involvement in pain states", MOL. NEUROBIOL., vol. 36, 2007, pages 165 - 183, XP055478666, DOI: doi:10.1007/s12035-007-0033-y |
Also Published As
Publication number | Publication date |
---|---|
US10981958B2 (en) | 2021-04-20 |
CA3045790C (en) | 2021-08-10 |
CN110062763B (zh) | 2022-11-15 |
JP6870091B2 (ja) | 2021-05-12 |
EP3584254A1 (en) | 2019-12-25 |
JP2020504098A (ja) | 2020-02-06 |
CN110062763A (zh) | 2019-07-26 |
EA037272B1 (ru) | 2021-03-02 |
EA201991365A1 (ru) | 2019-11-29 |
AU2017371488A1 (en) | 2019-07-18 |
EP3584254A4 (en) | 2020-07-15 |
CA3045790A1 (en) | 2018-06-14 |
KR20190090849A (ko) | 2019-08-02 |
AU2017371488B2 (en) | 2020-10-29 |
US20200207815A1 (en) | 2020-07-02 |
RU2650780C1 (ru) | 2018-04-17 |
KR102237590B1 (ko) | 2021-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6426217B2 (ja) | 核タンパク質の産生のための修飾ポリヌクレオチド | |
JP6203215B2 (ja) | プロミニン−1ペプチド断片およびその使用 | |
US20150050354A1 (en) | Modified polynucleotides for the treatment of otic diseases and conditions | |
JP2015518705A (ja) | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド | |
JP2015516143A6 (ja) | ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド | |
RU2650780C1 (ru) | Пептидный модулятор пуринергических рецепторов | |
RU2422459C1 (ru) | Пептидный модулятор пуринергических рецепторов | |
JP2023544141A (ja) | AIMP2-DX2および必要に応じてmiR-142の標的配列ならびにその組成物を使用した神経系疾患を処置する方法 | |
Zhang et al. | Purification, characterization and cDNA cloning of an analgesic peptide from the Chinese scorpion Buthus martensii Karsch (BmK AGP-SYPU2) | |
ES2700531T3 (es) | Fosforilación del factor de transcripción E2F4 en los restos Thr-248 y/o Thr-250 como diana terapéutica en procesos patológicos asociados a poliploidía somática | |
RU2521657C1 (ru) | Анальгетический пептид из морской анемоны urticina grebelnyi | |
US7662620B2 (en) | Human and mammalian stem cell-derived neuron survival factors | |
AU2002245934B2 (en) | Alpha conotoxin peptides with analgesic properties | |
EP1503758A1 (en) | Methods of modulating smooth muscle contractility | |
JP2000166572A (ja) | 神経伝導抑制作用を有するペプチド | |
WO2015035364A1 (en) | Proteins for targeting neuronal nitric oxide synthase to muscle sarcolemma and related methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17877931 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3045790 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2019531251 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20197019434 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017371488 Country of ref document: AU Date of ref document: 20170531 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017877931 Country of ref document: EP Effective date: 20190708 |